BRIEF published on 06/30/2026 at 19:13, 2 months 24 days ago ABIONYX Pharma Secures Funding to Advance Sepsis Treatment ABIONYX Pharma CER-001 Financial Funding Sepsis Treatment ApoA-I Platform
BRIEF published on 06/30/2026 at 19:13, 2 months 24 days ago ABIONYX Pharma en pleine expansion après son Assemblée Générale ABIONYX Pharma Sepsis CER-001 Assemblée Générale 2026 Plateforme ApoA-I
BRIEF published on 06/30/2026 at 19:13, 2 months 24 days ago ABIONYX Pharma is expanding rapidly following its General Meeting ABIONYX Pharma Sepsis CER-001 General Assembly 2026 ApoA-I Platform
PRESS RELEASE published on 06/30/2026 at 19:08, 2 months 24 days ago Inside Information / Other news releases ABIONYX Pharma scales up operations after securing resources, focusing on value creation in inflammation and sepsis treatment. Updates on pivotal clinical trial, financial visibility, and scientific platform development Financial Resources Clinical Trial ABIONYX Pharma Sepsis Inflammation Treatment
PRESS RELEASE published on 06/30/2026 at 19:08, 2 months 24 days ago Informations privilégiées / Autres communiqués ABIONYX Pharma change d'échelle suite à la sécurisation des moyens de son ambition et ouvre un nouveau cycle de création de valeur dans les inflammations sévères et le sepsis ABIONYX Pharma Sepsis Création De Valeur Innovantes Inflammations Sévères
BRIEF published on 06/18/2026 at 07:35, 3 months 6 days ago ABIONYX Pharma réussit son augmentation de capital Augmentation De Capital Essai Clinique Financement Obligataire Sepsis Fenja Capital
BRIEF published on 06/18/2026 at 07:35, 3 months 6 days ago ABIONYX Pharma Completes Successful EUR 33 Million Financing Capital Increase Bond Financing ABIONYX Pharma Fenja Capital Sepsis Research
BRIEF published on 06/18/2026 at 07:35, 3 months 6 days ago ABIONYX Pharma finalise avec succès un financement de 33 millions d'euros. Augmentation De Capital ABIONYX Pharma Fenja Capital Financement Par Obligations Recherche Sur La Septicémie
BRIEF published on 06/18/2026 at 07:35, 3 months 6 days ago ABIONYX Pharma successfully completes its capital increase Capital Increase Clinical Trial Bond Financing Sepsis Fenja Capital
PRESS RELEASE published on 06/18/2026 at 07:30, 3 months 6 days ago Inside Information / Other news releases ABIONYX Pharma successfully completes financing, raising EUR 33 M. Capital increase and bonds financing secured, enhancing financial position for future growth and clinical trials Financing Clinical Trials Capital Increase ABIONYX Pharma Bonds Financing
Published on 09/25/2026 at 00:30, 5 hours 50 minutes ago Viemed Healthcare Announces Adoption of Automatic Securities Disposition Plan by President Michael Moore
Published on 09/25/2026 at 00:15, 6 hours 5 minutes ago CoTec Holdings Corp. Announces Extension of Private Placement of Unsecured Convertible Debentures
Published on 09/24/2026 at 22:01, 8 hours 19 minutes ago Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 14:55, 15 hours 25 minutes ago Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/25/2026 at 02:45, 3 hours 34 minutes ago Huagui Group: un acteur mondial sur deux marchés aquatiques de plus de 100 milliards de RMB, tandis que la racine de lotus de Honghu se classe au premier rang pour sa teneur en antioxydants
Published on 09/25/2026 at 02:45, 3 hours 34 minutes ago Huagui Group: A Global Player Across Two RMB100-Billion Aquatic Markets, as Honghu Lotus Root Ranks No. 1 in Antioxidant Content
Published on 09/24/2026 at 20:29, 9 hours 50 minutes ago EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 11 hours 20 minutes ago HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 11 hours 39 minutes ago EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:31, 11 hours 48 minutes ago LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:00, 12 hours 20 minutes ago GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 12 hours 20 minutes ago GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
